Loading Events

COVID-19 Biomedical Research Webinar for Colorado Legislators + Policymakers

Wednesday, Jun 24, 2020

Join the COVID-19 Biomedical Research Webinar for Colorado Legislators + Policymakers with opening remarks by Jennifer Jones Paton, President & CEO of Colorado Bioscience Association and Dana Malick, Senior Director of State Policy for PhRMA.

If you’d like to attend this webinar, please send an email to jennifer@pharmalogic.us.

Host: Gregg Moss, City of Westminster Innovation Coordinator and former 9News Anchor/Business Reporter

Gregg Moss is a highly respected communicator who retired from Denver’s KUSA in 2016, where he had worked off and on as an anchor and reporter since 1993. His reporting focused on business. Moss has divided his time between media, business and nonprofit work over the years. Before joining 9News, he was the associate publisher for the Denver Business Journal.


Ed Harnaga, Pfizer Vice President of R&D Corporate Affairs

Ed Harnaga leads a team responsible for all scientific communications and innovation policy initiatives at Pfizer. This includes responsibility for supporting Pfizer’s R&D engine across the development spectrum – from the company’s earliest preclinical discovery efforts, to its mid-stage clinical pipeline. Operationally, Ed sits on the Leadership Teams of Pfizer’s Worldwide Research, Development and Medical organization and Corporate Affairs, and he is also responsible for supporting the company’s Global Product Development organization. Ed has taken part in numerous global task forces in the public affairs arena including the Council on Foreign Relations’ Task Force on Improving U.S. Public Diplomacy and the East-West Institute’s US-Russian Task Force against HIV/AIDS. Ed holds a Bachelor of Arts Degree from the State University of New York at Albany.

Michael Page, Alexion Pharmaceuticals Executive Director of Global Regulatory Affairs Strategy

At Alexion, Mr. Page leads a global team which develops and executes regulatory strategies for clinical trials and new drug approvals across the company’s rare disease product portfolio. Prior to joining Alexion, Mr. Page led the US Regulatory team for oncology at Eisai and managed the regulatory aspects of Eisai’s monoclonal antibody products. Mr. Page graduated as a Bachelor of Science in Biochemistry from the University of Hull, UK.

Dr. Gary Pestano, Biodesix Chief Development Officer

seasoned biotech leader, Dr. Pestano heads up Development and Operations at Biodesix. Dr. Pestano is the co-inventor on multiple national and international patents for diagnostic tests, and he received his Ph.D. training in Cell and Molecular Biology at The Graduate Center, City University of New York and conducted his post-doctoral training in cancer immunology at the Dana Farber Cancer Institute at Harvard Medical School.
Dr. Michael Ybarra, PhRMA Vice President of Medical Affairs & Strategic Alliances

Michael Ybarra, M.D. is a board-certified emergency physician and Senior Director of Alliance Development at PhRMA. In his capacity at PhRMA, Dr. Ybarra leads alliance outreach to provider, multicultural, and LGBT organizations. His issue areas include communications with health care professionals and delivery reform. In addition to his work at PhRMA, Dr. Ybarra works clinically in the Emergency Department at MedStar Georgetown University Hospital. Dr. Ybarra is a graduate of Stanford University, Georgetown University School of Medicine, and completed residency training at MedStar Washington Hospital Center.

This event sponsored by: